Late-Breaking Clinical Trials

Updated:Aug 25,2015
Scientific Sessions 2015 - November 7-11, 2015
 

Become a Member

Join or renew your AHA/ASA Professional Membership today to save on registration for all AHA Scientific Sessions.


Late Breaking Clinical Trial Submission is closed.

Registration Information

Registration is now open!

Register Online and Save $20

Late-Breaking Clinical Trials


Late-Breaking Clinical Trials sessions are innovative, provide the latest breakthroughs in clinical science and potentially will have a significant impact on clinical practice. Clinical Science Report sessions will highlight trial updates, registries and important clinical science.

Here are highlights of the recently selected 2015 Late-Breaking Clinical Trials. Complete details will be available soon.  

Heart Failure

FIGHT: GLP-1 Receptor Agonist in HFpEF
Outcome of GLP-1 receptor agonist treatment on clinical status at 180 days for high-risk HFpEF patients.
NEAT HFpEF: Nitrates and Activity in HFpEF
Ability of nitrates to improve activity tolerance in ambulatory HFpEF patients.
SOCRATES/ REDUCED: Vericiguat Use in Chronic HF
Safety and effectiveness of vericiguat to reduce NT-ProBNP and improve echocardiographic measurements and QOL in worsening chronic HF.
BEAT HF: Telemonitoring After Discharge
Effectiveness of incorporating the care transition approach with telemonitoring on remote patient management after hospital discharge.  

Resuscitation

ROC-CCC: Continuous vs Interrupted Chest Compressions in CPR
Outcomes of continuous versus interrupted chest compressions in out of hospital arrest.
PROACT 4: Point-of-Care Troponin Testing and Time-to-Diagnosis for Acute CV Symptoms
Point-of-care troponin testing and time-to-diagnosis for acute CV symptoms to provide rapid out-of-hospital acute CV treatment.

Prevention/Lifestyle

EVITA: Varenicline Use in Smoking Cessation
Determined the safety and efficacy of varenicline, when started in the hospital after ACS, in smoking cessation.
50/50: Peer Group Intervention in Risk Factor Modification
Peer-group intervention on improving CV risk factors such as tobacco, other substance abuse, eating disorders and chronic illnesses.
MBC2: Genetic Risk Score Knowledge in Cholesterol Lowering
Does knowledge of a genetic risk score for coronary heart disease result in lower low-density lipoprotein cholesterol?
EMPA-REG OUTCOME: Empagliflozin Use in Patients with Type 2 DM
Safety and effectiveness of blood-glucose lowering by pharmacological inhibition of the sodium glucose co-transporter 2 in lowering CVD risk in high-risk patients with type 2 diabetes.

Interventional

RIVER-PCI: Ranolazine Use for Incomplete Revascularization
Effectiveness of ranolazine in reducing post-PCI angina and ischemic events in the long-term management of patients with incomplete revascularization.
IVUS XPL: Everolimus-Eluting Stents in Long Coronary Lesions
Intravascular Ultrasound-Guided Everolimus-Eluting Stents Implantation in long coronary lesions—clinical outcomes.
PEGASUS-TIMI 54: Long-Term Ticagrelor Efficacy and Compliance
Efficacy of long-term ticagrelor compliance; why stable, prior MI patients discontinue it.
DAPT Study Analysis: Individualizing DAPT After PCI
Individualization of the duration of dual antiplatelet therapy after PCI.

Novel Therapies (First in Man)

AUGMENT HF: Advanced HF Treatment with Algisyl at 1 year
1-Year Efficacy Follow-up: LV augmentation with Algisyl-LVR in moderate to advanced HF treatment.
BEAT-HF (B3): Efficacy of an Oral β3-Adrenoceptor Agonist in Chronic HF
First-in-man randomized trial of an oral β3-adrenoceptor agonist in chronic heart failure.
PRADA: Preventing Cardiac Dysfunction During Breast Cancer Therapy
Primary results of a RCT for the prevention of cardiac dysfunction during adjuvant breast cancer therapy.
ANNEXA-R: Sustained Reversal of Rivaroxaban Anticoagulation in Elderly by Andexanet Alfa
A phase 3 RCT demonstrating sustained reversal of Rivaroxaban-induced anticoagulation in older subjects by Andexanet Alfa, a universal antidote for Factor XA Inhibitors.
Preventing Renal Injury with Nitric Oxide During CPB
Nitric Oxide and preventing acute kidney injury during and after prolonged cardiopulmonary bypass.
RWISE: Ranolazine and Microvascular Coronary Dysfunction
Effectiveness of ranolazine in reducing angina in patients with microvascular coronary dysfunction. 

Registries

ENDOCARDITIS: Infective Endocarditis After 2009 ESC Guideline
Evaluation of the incidence of infective endocarditis following the 2009 ESC Guideline Update.
SHARE-HCM: Sarcomere Mutations and Clinical Severity
Analysis of sarcomere mutations and their relationships to severity of clinical profile in genotyped HCM patients.
CANOA: Clopidogrel and Aspirin for Migraine After Transcatheter ASD Closure
Effectiveness of clopidogrel in addition to aspirin for preventing new-onset migraine attacks subsequent to transcatheter atrial septal defect closure.
EWOLUTION: LA Appendage Occlusion and Stroke with WATCHMAN Device
Left Atrial Appendage Occlusion effectiveness and non-inferiority compared to oral anticoagulation in AF patients related to procedural success and complications as a stroke reduction strategy with the WATCHMAN device.

Registries/EP

Medicare ICD Registry Analysis: Wide QRS, RBBB and CRT
Medicare ICD Registry Analysis of Cardiac Resynchronization Therapy in patients with Wide QRS and Right Bundle Branch Block.
Micra Transcatheter Pacing Study: Miniaturized, Leadless, Transcatheter-Delivered Cardiac Pacing
Miniaturized, leadless, transcatheter-delivered cardiac pacing.
Video Decision Support Tool for Patients with Advanced HF
Video decision support tool to depict goals of care and resuscitation options for patients with advanced HF.

Updates

JUPITER: Variability in LDL Cholesterol Response to Statin
Individual variability in LDL cholesterol response to statin therapy and the relationship of on-treatment lipid level magnitude with event reduction.
CAN HEART: HDL Cholesterol and Mortality
Importance of HDL cholesterol in predicting CV and non-cardiovascular mortality in 630,000 persons without prior CVD.
ACCORDIAN BP:  Long-Term CV Effects of 4.9 Years of Intensive BP Control in Type 2 DM
Long-term CV effects of 4.9 years of intensive blood pressure control in Type 2 Diabetes Mellitus.
REVASC DM:  Benefits of CABG vs. PCI in Diabetic Patients via Registries and Cohort Studies
Benefits of CABG vs. PCI in diabetic patients from clinical registries or cohort studies.


Submission Guidelines